KaNDy Therapeutics Company

KaNDy Therapeutics is a clinical-stage company focused on optimising the potential of NT-814. KaNDy Therapeutics develops a breakthrough non-hormonal treatment for multiple symptoms of the menopause including hot flashes and nighttime awakening. Launched in 2017, KaNDy Therapeutics is based at the state-of-the-art Stevenage Bioscience Catalyst, the UK’s first open innovation bioscience campus.
Technology: Cancer
Industry: Longevity
Headquarters: Stevenage, Herefordshire, United Kingdom
Founded Date: 2017
Employees Number: 1-10
Funding Status: M&A
Investors Number: 5
Total Funding: $32 589 510
Estimated Revenue: $1M to $10M
Last Funding Date: 2018-08-29
Last Funding Type: Series C

Visit Website
Register and Claim Ownership